ERXY

ERXY is committed to the early diagnosis of neurodegenerative diseases and has developed China's first non-invasive blood test product for PD based on an automated platform for targeted exosome enrichment.ERXY has developed targeted exosome enrichment technology and created the world’s first automated targeted exosome enrichment platform, for which multiple domestic and international patents have been filed.ERXY has established several diagnostic product pipelines. Its total exosome extraction kit and neuron exosome extraction kit received certification and were launched in 2022. Currently, ERXY has completed the development of China's first non-invasive blood test product for PD, which has passed the Beijing Innovative Medical Device Review and is undergoing registrational clinical trials.